Modality
Gene Editing
MOA
Anti-Tau
Target
FLT3
Pathway
STING
Endometrial CaBCC
Development Pipeline
Preclinical
Apr 2020
→ Dec 2025
PreclinicalCurrent
NCT05298155
826 pts·BCC
2020-04→2025-12·Completed
826 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-124mo agoInterim· BCC
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2025-12-12 · 4mo ago
BCC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05298155 | Preclinical | BCC | Completed | 826 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Voxamavacamten | Corcept | Approved | BET |